IMMUNO-CLUSTER

TO1

Strengthening research, technological development and innovation

The project in numbers
Duration:
30 months
Start date: 01.01.20
End date: 30.06.22
N. Partner: 6
 
Progress
Budget:
881.299,10€
Budget FERS:
749.104,22€

The project in numbers

Duration: 
30 months
Start / End: 
01.01.20 to 30.06.22
Project progress: 
100%
Budget: 
881299.10€
Budget FERS: 
749104.22€

IMMUNO-CLUSTER

Immuno-Cluster
Priority Axis 1

Promoting innovation capacities for a more competitive area

Specific Objective: 
OS 1.1.
Investment Priority: 
PI 1b
Typology: 
Standard
Overall Objective of the Project: 

New Immuno-Cluster. Pilot project to improve quality and life expectancy of women with Triple Negative Breast Carcinoma (TNBC) focused on HybriCure® immunoibridioma (Celica), bioreactors (VivaBioCell, NANT) for automated production, innivative SMEs , hospitals / Lead User. Immuno-Cluster creates a system of common resources (qualified personnel, know-how) among project partners and local private and public actors for TNBC therapy improving the quality and life expectancy of women in the area (at the moment, there are no satisfactory treatments). 

Project summary: 

The purpose of the Immuno-Cluster project was to establish cross-border cooperation through clinical research for the treatment of triple-negative breast cancer using an autologous cell vaccine (immunohybridomas), which was introduced years ago by the leading partner (Celica Biomedical). In this project, in addition to the preparation of a protocol for a new clinical study, there was also an increase in production in "closed" bioreactors. For this purpose, the validation of the preparation of dendritic cells on the so-called "open" mode (Celica Biomedical) and on the so-called "closed" method of production with an automatic bioreactor (VivaBioCell). The results of the measurements showed the consistency of the two methodologies and the success of the validation of the two technologies created greater access to the treatment of patients in the region through the introduction of transregional clinical studies. The project thus made it possible to perfectly connect top hospitals with pharmaceutical and biotechnology companies, universities and research centers that operate at the highest European and global level. As part of the project, the activities and results of the project were also disseminated outside the program area, namely at EXPO 2020, which took place in Dubai in January 2022 (due to the pandemic), where a new method of treating solid cancers was presented for the first time. on an international level.

Main results: 

The main goal of the project was the preparation of a joint clinical protocol for triple-negative breast cancer with the cross-border contribution of three clinics and the approval of local ethics committees from Slovenia and Italy. By achieving this goal, together with the production scale-up and validation of two dendritic cell preparation technologies, a foundation has been created for future good practice for transnational clinical research in the region in the future. This was only possible through cooperation and through the upgrading of the exchange of expertise of various partners on a transnational level, where research institutions, clinics and companies working in the field of regenerative medicine and biomedical research into the introduction of cellular medicines for advanced treatment participated. The international public was informed about the results of this project through a high-profile presentation in the pavilion of the Republic of Slovenia in January 2022 at EXPO 2020, Dubai.

Partner

Lead Partner

Celica Biomedical d.o.o.

Osrednjeslovenska
SLO

Project partner 1

Onkološki inštitut Ljubljana

Osrednjeslovenska
SLO

Project partner 2

Ortopedska bolnišnica Valdoltra

Obalno-kraška
SLO

Project partner 3

VivaBioCell S.p.A.

Udine
ITA

Project partner 4

Università degli Studi di Udine – Dipartimento di Area Medica

Udine
ITA

Project partner 5

Regione del Veneto. Azienda unità locale socio sanitaria n°3 Serenissima

Venezia
ITA

Objectives and Activities

KEY PROJECT OBJECTIVES

New Immuno-Cluster. Pilot project to improve quality and life expectancy of women with Triple Negative Breast Carcinoma (TNBC) focused on
HybriCure® immunoibridioma (Celica), bioreactors (VivaBioCell, NANT) for automated production, innivative SMEs , hospitals / Lead User. Immuno-Cluster creates a system of common resources (qualified personnel, know-how) among project partners and local private and public actors for TNBC therapy improving the quality and life expectancy of women in the area (at the moment, there are no satisfactory treatments).

CURRENT STATUS OF IMPLEMENTATION

The Project started on 1/1/2020.

Contacts

Celica Biomedical d.o.o.

00386 41334095
Tehnološki park 24 1000 Ljubljana Slovenija
office@celicabiomedical.com
Zorec Robert
robert.zorec@celicabiomedical.com

Onkološki inštitut Ljubljana

00386 41812931
Zaloška cesta 2 1000 Ljubljana Slovenija
raziskovanje@onko-i.si
Borštnar Simona
sborstnar@onko-i.si

Ortopedska bolnišnica Valdoltra

00386 5 6696 393
Jadranska cesta 31 6280 Ankaran Slovenija
valdoltra@ob-valdoltra.si
Cör Andrej
andrej.coer@ob-valdoltra.si

VivaBioCell S.p.A.

335 6068088
Via del Cotonificio 27 33100 Udine (UD) Italia
info@vivabiocell.it
Sfiligoj Antonio
antonio.sfiligoj@vivabiocell.it

Università degli Studi di Udine – Dipartimento di Area Medica

0039335 1605117
Via Palladio 8 33100 Udine (UD) Italia
ricerca.dame@unid.it
Curcio Francesco
francesco.curcio@uniud.it

Regione del Veneto. Azienda unità locale socio sanitaria n°3 Serenissima

0039419657175
Via don F. Tosatto 147 30174 Venezia (VE) Italia
azienda.sanitaria@aulss3.veneto.it
Gessoni Gianluca
gianluca.gessoni@aulss3.veneto.it